Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

Searched for: Liver Cancer. 7 results shown below.

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

[Complete title: Treatment of Children with All Stages of Hepatoblastoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AHEP0731
Phase: III

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

[Complete title: A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patient with Unresectable Hepatocellular Carcinoma (HCC)]
Principal Investigator: William Harris
Study Number: 20111617
Phase: III

Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy

[Complete title: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy]
Principal Investigator: William Harris
Study Number: 20122073
Phase: III

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

[Complete title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib]
Principal Investigator: William Harris
Study Number: 20130857
Phase: III

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

[Complete title: A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma]
Principal Investigator: William Harris
Study Number: 20131240
Phase: III

Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer

[Complete title: A Phase 1 Study of ADI-PEG 20 Plus Sorafenib in Subjects WithAdvanced Hepatocellular Carcinoma (HCC)]
Principal Investigator: William Harris
Study Number: 20142070
Phase: I

A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors

[Complete title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC), MELANOMA, CLEAR CELL RENAL CELL CARCINOMA (RCC) OR SQUAMOUS CELL HEAD AND NECK CANCER (SCCHN)]
Principal Investigator: John Thompson, MD
Study Number: 20150061
Phase: I

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials